JP2017510575A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017510575A5 JP2017510575A5 JP2016558161A JP2016558161A JP2017510575A5 JP 2017510575 A5 JP2017510575 A5 JP 2017510575A5 JP 2016558161 A JP2016558161 A JP 2016558161A JP 2016558161 A JP2016558161 A JP 2016558161A JP 2017510575 A5 JP2017510575 A5 JP 2017510575A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- sequence
- fusion polypeptide
- disease
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461954437P | 2014-03-17 | 2014-03-17 | |
| US61/954,437 | 2014-03-17 | ||
| PCT/JP2015/058645 WO2015141862A1 (en) | 2014-03-17 | 2015-03-16 | Antibody-fynomer conjugates |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017510575A JP2017510575A (ja) | 2017-04-13 |
| JP2017510575A5 true JP2017510575A5 (enExample) | 2017-08-10 |
| JP6345800B2 JP6345800B2 (ja) | 2018-06-20 |
Family
ID=54144822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016558161A Active JP6345800B2 (ja) | 2014-03-17 | 2015-03-16 | 抗体−フィノマー複合体 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US10323095B2 (enExample) |
| EP (1) | EP3119885B1 (enExample) |
| JP (1) | JP6345800B2 (enExample) |
| KR (1) | KR102473544B1 (enExample) |
| CN (1) | CN106211782B (enExample) |
| AU (1) | AU2015232352B2 (enExample) |
| CA (1) | CA2942546C (enExample) |
| DK (1) | DK3119885T3 (enExample) |
| ES (1) | ES2881602T3 (enExample) |
| HU (1) | HUE055424T2 (enExample) |
| MX (1) | MX374483B (enExample) |
| PH (1) | PH12016501816B1 (enExample) |
| PL (1) | PL3119885T3 (enExample) |
| PT (1) | PT3119885T (enExample) |
| RU (1) | RU2732226C2 (enExample) |
| TW (1) | TWI674274B (enExample) |
| WO (1) | WO2015141862A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| CN109071613A (zh) | 2016-05-11 | 2018-12-21 | 通用电气医疗集团生物工艺研发股份公司 | 分离基质 |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US11753438B2 (en) | 2016-05-11 | 2023-09-12 | Cytiva Bioprocess R&D Ab | Method of cleaning and/or sanitizing a separation matrix |
| US11708390B2 (en) | 2016-05-11 | 2023-07-25 | Cytiva Bioprocess R&D Ab | Method of storing a separation matrix |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| EP3824906A1 (en) | 2016-12-21 | 2021-05-26 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| US10722589B2 (en) | 2017-04-03 | 2020-07-28 | Covagen Ag | FGFR3 binding molecules |
| US20190153096A1 (en) | 2017-10-02 | 2019-05-23 | Covagen Ag | Cd3/cd33 bispecific binding molecules |
| US20190100587A1 (en) | 2017-10-02 | 2019-04-04 | Covagen Ag | IgG1 Fc MUTANTS WITH ABLATED EFFECTOR FUNCTIONS |
| BR112021005465A2 (pt) * | 2018-10-02 | 2021-06-15 | Mitsubishi Tanabe Pharma Corporation | agentes de ligação biespecíficos direcionados ao sindecano-1 e receptor do fator de crescimento de fibroblasto |
| JP7562528B2 (ja) | 2018-12-28 | 2024-10-07 | 四川科倫博泰生物医薬股▲フン▼有限公司 | 抗体及びその用途 |
| KR20210151774A (ko) | 2019-04-16 | 2021-12-14 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 항-FXI/FXIa 항체 및 그 용도 |
| KR20220070201A (ko) | 2019-09-30 | 2022-05-30 | 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 | 항-pd-1 항체 및 이의 용도 |
| CA3155759A1 (en) | 2019-12-13 | 2021-06-17 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Anti-tslp antibody and uses thereof |
| PE20230373A1 (es) | 2020-05-15 | 2023-03-06 | Sichuan Kelun Biotech Biopharmaceutical Co Ltd | Conjugado anticuerpo-farmaco, metodo de preparacion del mismo y uso del mismo |
| AU2021372706A1 (en) | 2020-10-26 | 2023-06-08 | Akeso Biopharma, Inc. | Anti-tigit antibody, and pharmaceutical composition and use thereof |
| KR20230125037A (ko) | 2020-12-31 | 2023-08-28 | 노나 바이오사이언시즈 (수조우) 컴퍼니 리미티드 | 인간 lifr 항원 결합 단백질, 이의 제조 방법, 및 이의응용 |
| WO2022157493A1 (en) | 2021-01-21 | 2022-07-28 | Eusa Pharma (Uk) Limited | Method for treating il-6 associated histiocytic and lymphoproliferative disorders |
| CA3207635A1 (en) | 2021-03-09 | 2022-09-15 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Ror1 binding protein and use thereof |
| MX2024001067A (es) | 2021-07-23 | 2024-02-27 | Akeso Biopharma Inc | Composicion farmaceutica y uso. |
| EP4405396A2 (en) | 2021-09-20 | 2024-07-31 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| US20250034559A1 (en) | 2021-11-17 | 2025-01-30 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN114181310B (zh) | 2022-02-14 | 2022-07-05 | 中山康方生物医药有限公司 | 抗tigit抗体、其药物组合物及用途 |
| CN114853890B (zh) | 2022-03-16 | 2023-04-28 | 沈阳三生制药有限责任公司 | 一种prlr抗原结合蛋白及其制备方法和应用 |
| CN116925233A (zh) | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗tigit-抗pvrig双特异性抗体、其药物组合物及用途 |
| CN116925222A (zh) | 2022-04-02 | 2023-10-24 | 普米斯生物技术(珠海)有限公司 | 抗pvrig抗体、其药物组合物及用途 |
| EP4522757A2 (en) | 2022-05-13 | 2025-03-19 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of her2 positive cancer |
| WO2024228389A1 (ja) * | 2023-05-02 | 2024-11-07 | 田辺三菱製薬株式会社 | 対象における二重特異性融合ポリペプチドの有効性を予測するための方法 |
| WO2025054768A1 (en) * | 2023-09-11 | 2025-03-20 | Eluminex Biosciences (Suzhou) Limited | Multispecific fusion proteins targeting angiogenic and inflammatory factors |
| WO2025122634A1 (en) | 2023-12-05 | 2025-06-12 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| WO2025224095A1 (en) | 2024-04-22 | 2025-10-30 | Recordati Netherlands Bv | Use of inhibitors of il-6 or il-6r for treating graft versus host disease in a subject |
| PL448731A1 (pl) * | 2024-05-31 | 2025-12-01 | Celon Pharma Spółka Akcyjna | Przeciwciała bispecyficzne anty–IL-17A i anty-IL-6 oraz ich zastosowanie w terapii, zwłaszcza w leczeniu chorób immunologicznych |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| CN101874042B9 (zh) | 2007-09-26 | 2019-01-01 | 中外制药株式会社 | 利用cdr的氨基酸取代来改变抗体等电点的方法 |
| EP2297202B1 (en) | 2008-05-13 | 2016-01-13 | NovImmune SA | Anti-il-6/il-6r antibodies and methods of use thereof |
| AU2009256250B2 (en) * | 2008-06-03 | 2013-05-30 | Abbvie Inc. | Dual variable domain immunoglobulins and uses thereof |
| TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
| WO2011023685A1 (en) * | 2009-08-27 | 2011-03-03 | Covagen Ag | Il-17 binding compounds and medical uses thereof |
| TWI609698B (zh) | 2010-01-20 | 2018-01-01 | Chugai Pharmaceutical Co Ltd | 穩定化的含抗體溶液製劑 |
| US8524217B2 (en) | 2010-05-11 | 2013-09-03 | Merck Sharp & Dohme Corp. | MCP1-Ig fusion variants |
| EP2597102A1 (en) * | 2011-11-25 | 2013-05-29 | Covagen AG | A novel fusion protein comprising an antibody light chain and a polypeptide binding to IL-17 |
| EP2791171A1 (en) * | 2011-12-16 | 2014-10-22 | Synthon Biopharmaceuticals B.V. | EXPRESSION OF SECRETORY IgA ANTIBODIES IN DUCKWEED |
| EP2638916A1 (en) * | 2012-03-16 | 2013-09-18 | Covagen AG | Novel binding molecules with antitumoral activity |
| NZ629283A (en) * | 2012-03-16 | 2016-04-29 | Covagen Ag | Novel binding molecules with antitumoral activity |
| EP2711016A1 (en) * | 2012-09-21 | 2014-03-26 | Covagen AG | Novel IL-17A binding molecules and medical uses thereof |
-
2015
- 2015-03-16 DK DK15765900.4T patent/DK3119885T3/da active
- 2015-03-16 TW TW104108275A patent/TWI674274B/zh active
- 2015-03-16 PL PL15765900T patent/PL3119885T3/pl unknown
- 2015-03-16 PT PT157659004T patent/PT3119885T/pt unknown
- 2015-03-16 CN CN201580014271.5A patent/CN106211782B/zh active Active
- 2015-03-16 JP JP2016558161A patent/JP6345800B2/ja active Active
- 2015-03-16 RU RU2016140572A patent/RU2732226C2/ru active
- 2015-03-16 EP EP15765900.4A patent/EP3119885B1/en active Active
- 2015-03-16 KR KR1020167028719A patent/KR102473544B1/ko active Active
- 2015-03-16 HU HUE15765900A patent/HUE055424T2/hu unknown
- 2015-03-16 ES ES15765900T patent/ES2881602T3/es active Active
- 2015-03-16 CA CA2942546A patent/CA2942546C/en active Active
- 2015-03-16 AU AU2015232352A patent/AU2015232352B2/en active Active
- 2015-03-16 MX MX2016012010A patent/MX374483B/es active IP Right Grant
- 2015-03-16 US US15/126,551 patent/US10323095B2/en active Active
- 2015-03-16 WO PCT/JP2015/058645 patent/WO2015141862A1/en not_active Ceased
-
2016
- 2016-09-16 PH PH12016501816A patent/PH12016501816B1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017510575A5 (enExample) | ||
| RU2016140572A (ru) | Конъюгаты антитело-финомер | |
| JP2021507690A5 (enExample) | ||
| JP2011526792A5 (enExample) | ||
| JP2019058197A5 (enExample) | ||
| JP2020171316A5 (enExample) | ||
| JP2016518823A5 (enExample) | ||
| JP2021008468A5 (enExample) | ||
| RU2012111597A (ru) | Новые il-17-связывющие соединения и их медицинское применение | |
| JP2014513953A5 (enExample) | ||
| JP2015511637A5 (enExample) | ||
| HRP20200230T1 (hr) | Polipeptidi antitijela koji antagoniziraju cd40l | |
| NZ590466A (en) | Treatment of inflammatory diseases with mammal beta defensins | |
| JP2012516158A5 (enExample) | ||
| JP2016510736A5 (enExample) | ||
| ES2822431T3 (es) | Polipéptidos de unión a IL-17A | |
| HRP20231399T1 (hr) | Fcrn antitijela i načini njihove uporabe | |
| JP2012517818A5 (enExample) | ||
| RU2011135422A (ru) | Человеческие анти-il-6 антитела с пролонгированным периодом выведения in vivo и их применение при лечении онкологических, аутоиммунных заболеваний и воспалительных заболеваний | |
| RU2011102579A (ru) | СТАБИЛЬНЫЕ И РАСТВОРИМЫЕ АНТИТЕЛА, ИНГИБИРУЮЩИЕ TNFα | |
| RU2003120859A (ru) | Способ ингибирования активности человеческого tnfa (варианты), применение выделенного антитела человека или его антиген-связывающего фрагмента в качестве компонента для производства лекарственного средства (варианты) и выделенное человеческое антитело или его антиген-связывающий фрагмент | |
| CN101484472A (zh) | 改善的sgp130Fc二聚体 | |
| JP2014511844A5 (enExample) | ||
| CN103380143A (zh) | 结合il-23的基于纤连蛋白的支架结构域蛋白质 | |
| JP2009526084A5 (enExample) |